Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observationa
Lung cancer is a malignant tumor with the highest incidence and mortality rate of cancer patients worldwide. Traditional treatments for lung cancer include surgery, radiotherapy and chemotherapy, etc. Although the growth and spread of the tumor can be controlled to a certain extent, the cure rate for patients with prog
| Condition(s) | Lung Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Lung cancer is a malignant tumor with the highest incidence and mortality rate of cancer patients worldwide. Traditional treatments for lung cancer include surgery, radiotherapy and chemotherapy, etc. Although the growth and spread of the tumor can be controlled to a certain extent, the cure rate for patients with progressive stage is still low and the prognosis is poor. Neoadjuvant therapy intends to use chemotherapy, immunotherapy, and targeted therapy to reduce the size and load of the tumor before surgery, to improve the surgical resection rate and therapeutic effect. 1. Primary research objective: to explore the therapeutic efficacy of patients with different characteristics under different neoadjuvant therapeutic regimens. 2. Secondary objectives To investigate the strengths and weak |
| Who can participate | Inclusion Criteria: 1. Age greater than or equal to 18 years; 2. Pathohistologically confirmed diagnosis of non-small cell lung cancer or small cell lung cancer; 3. Received neoadjuvant therapy after diagnosis; 4. Written informed consent. Exclusion Criteria: 1. Patients enrolled in other clinical trials; 2. Patients refused enrollment in this study; 3. Patients refused follow-up. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Locations | Shanghai, Shanghai Municipality, China |
| Start date | 2023-12-16 |
| NCT ID | NCT06216782 |
| Official listing | https://clinicaltrials.gov/study/NCT06216782 |